In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.

Scientists have discovered that a rare immune cell type in the lungs, called NAMs, plays a crucial role in surviving COVID-19 ...

As symptoms progress, complications may occur, particularly in infants, who can be subject to pneumonia, heart failure, collapsed lung, brain bleeds and even ... asthma and chronic obstructive ...

Future research should focus on illuminating how different interstitial lung disease subtypes affect outcomes in AAV. Interstitial lung disease (ILD) patterns differ between patients with ...

tuberculosis, says Medha Singh, Ph.D., the study’s first author and a pediatric infectious diseases fellow in the school of medicine, promoting necrotic niches within the lung that prevent immune ...

However, in a small number of cases do not benefit from this treatment and instead experience rapid tumor progression, known as hyperprogressive disease (HPD ... unresectable squamous cell carcinoma ...